TrialArthritis research & therapy2014

CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'.

Stinne Ravn Greisen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.